The MVP is a mega-biobank supported by the U.S. Department of Veterans Affairs (VA), enrollment for which began in 2011 and is ongoing. Phenotypic data were collected using questionnaires and the VA electronic health records (EHR), and a blood sample was obtained from each participant for genetic studies. Two phases of genotypic data have been released and were included in this study. MVP phase1 contains 353,948 subjects, of whom 202,004 European Americans (EA) with AUD diagnoses were included in a previous GWAS and the summary statistics were used in this study [3]. MVP phase2 released data on another 108,416 subjects, of whom 65,387 EAs with AUD diagnosis information were included in this study. Following the same procedures as for MVP phase1, participants with at least one inpatient or two outpatient alcohol-related ICD-9/10 codes from 2000 to 2018 were assigned a diagnosis of AUD.
